Calculus Capital Limited / Stargrove Pictures Limited UK Creative Content EIS Fund

Hardman & Co

Why invest

Positives

  • Strategy: To invest in a portfolio of unquoted media companies that will generate meaningful IP.

Issues

  • Time to invest: The target time to invest of 15 months is longer than for some other EIS funds.

The Investment Manager

Positives

  • Team: One of the longest standing managers in the VCT/EIS area, Calculus has a highly experienced and stable team.

Issues

  • Past performance: While Calculus has a substantial and credible record from investing in other sectors, this is a new area for the team. However, the addition of Stargrove brings sector experience.

Nuts & bolts

  • Offer period: Closing dates are quarterly on last Fridays of October, January, April and June.
  • Diversification: The aim is to invest in at least six companies.
  • Valuation: Investors will receive valuations twice a year. Industry guidelines will be used, with two auditors examining the figures.

Specific issues

  • Fees: Mixture of direct fees and charged via the investee companies.
  • Performance fee: 20% on gains over a hurdle rate of 1.2x total capital invested.

Risks

  • Risk mitigation: Although a new sector for the Manager, Calculus will use its established investment processes and has brought in a specialist advisor in Stargrove.
  • Target return: Overall, the strategy is medium-risk relative to other EIS/VCT products, with the target capital return of 2.0x towards the top end of what we’d expect for that risk category.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

UK skills shortage puts infrastructure delivery under pressure

The UK's infrastructure pipeline is increasing demand for skilled workers, making recruitment, training and workforce technology increasingly important to project delivery.

Meridian takes Expanse Studios to global gaming expo

Meridian’s Expanse Studios heads to G2E Las Vegas with nearly 100 casino titles, 1,800-plus casino brands and regulatory coverage across more than 15 markets.

Personal Group praised by Fund Manager for income growth and market share gains

Premier Miton’s Gervais Williams discusses Personal Group Holdings’ 22% rise in adjusted EBITDA, record insurance sales, improving market share and prospective dividend yield of around 6%.

Cizzle Bio pushes blood test into lung cancer screening

Cizzle Bio is developing a blood test designed to add biomarker information to existing lung cancer screening.

European stocks rise as falling oil prices ease market pressure

European shares rose as lower oil prices eased pressure on markets, with investors now focused on September business activity data for clues about economic growth and interest rates.

The Biotech Growth Trust plc – Why Biotech’s Recovery Could Still Have Further to Run (video)

Biotech valuations have rebounded, pharmaceutical M&A has accelerated and regulatory uncertainty has begun to ease — but Josh Golomb of The Biotech Growth Trust believes the more important story is that innovation never stopped.

    Search